Suboptimal RAASi Therapy After Hyperkalemia Ups Cardiorenal Risks

Pills in hand with pill box
Guidelines support the use of RAASi at the maximum tolerated dose in patients with CKD and heart failure.

Cardiorenal risks increase following discontinuation or downtitration of renin-angiotensin-aldosterone system inhibitors (RAASi) due to hyperkalemia in patients with heart failure and/or stage 3 to 4 chronic kidney disease (CKD), investigators report.

Eiichiro Kanda, MD, PhD, MPH, of Kawasaki Medical School in Okayama, Japan, and colleagues identified 15,488 and 6020 patients who experienced a hyperkalemia episode during 2019 to 2021 from health registers in the US (Optum’s de-identified Market Clarity Data) and Japan (Medical Data Vision), respectively. Before the hyperkalemia episode, 59% and 27% of patients from the US and Japan, respectively, had achieved more than 50% of the target RAASi dose. After the hyperkalemia episode, 33% and 32%, respectively, did not fill a new RAASi prescription, and 7% and 6%, respectively, downtitrated at least 1 RAASi dose by more than 25%. Only 1% of patients initiated a novel potassium binder such as sodium zirconium cyclosilicate or patiromer following hyperkalemia.

The cardiorenal composite outcome occurred within 6 months in significantly higher proportions of patients in the US (17.5% and 18.3% vs 10.6%) and in Japan (19.7% and 20.0% vs 15.1%) who discontinued or downtitrated RAASi versus maintained/uptitrated RAASi, respectively. In adjusted analyses, the risk for the cardiorenal composite outcome was a significant 55% and 24% higher among patients in the US and Japan, respectively, who discontinued vs maintained their RAASi treatment, Dr Kanda’s team reported in BMC Nephrology. The composite outcome included a heart failure hospitalization or emergency department visit or progression to end-stage kidney disease. RAASi included angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, angiotensin receptor-neprilysin inhibitors, and mineralocorticoid receptor antagonists (except for finerenone).

“These data emphasize the importance of RAASi optimization following an episode of [hyperkalemia] and the need for targeted treatment of [hyperkalemia] to facilitate optimal RAASi management,” according to Dr Kanda’s team.

Disclosure: This research was supported by AstraZeneca. Please see the original reference for a full list of disclosures.


Kanda E, Rastogi A, Murohara T, et al. Clinical impact of suboptimal RAASi therapy following an episode of hyperkalemia. BMC Nephrol 24(1):18. doi:10.1186/s12882-022-03054-5

This article originally appeared on Renal and Urology News